Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,514
  • Shares Outstanding, K 15,514
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,190 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +322,358.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +1.00%
on 12/31/25
1.2700 -20.47%
on 12/03/25
-0.2000 (-16.53%)
since 11/28/25
3-Month
1.0000 +1.00%
on 12/31/25
1.7800 -43.26%
on 10/08/25
-0.6100 (-37.65%)
since 09/30/25
52-Week
0.6600 +53.03%
on 04/08/25
3.8000 -73.42%
on 01/07/25
+0.2489 (+32.70%)
since 12/30/24

Most Recent Stories

More News
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) , a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic...

HOTH : 0.9900 (-1.00%)
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

NobleCon is the preeminent showcase of small and microcap companies

HOTH : 0.9900 (-1.00%)
Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it...

HOTH : 0.9900 (-1.00%)
2 Stocks to Buy Under $10 That Wall Street Loves

While penny stocks are risky, they also have the potential to deliver outsized gains.

LTRN : 3.03 (-0.88%)
HOTH : 0.9900 (-1.00%)
ARCT : 6.07 (-1.94%)
Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health.

HOTH : 0.9900 (-1.00%)
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances.

HOTH : 0.9900 (-1.00%)
Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network...

HOTH : 0.9900 (-1.00%)
Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Presentation to highlight advancements in Hoth's clinical pipeline, including HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven...

HOTH : 0.9900 (-1.00%)
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001...

HOTH : 0.9900 (-1.00%)
Crypto and Cancer: How Biotech’s New Strategy Is Turning Heads

Innovation in %Biotech often comes from pushing both science and finance into new territory. As drug developers race toward clinical trials, two levers often distinguish those that succeed: strong intellectual...

MSTR : 153.66 (-1.25%)
BMNR : 27.55 (-0.61%)
^BTCUSDT : 88,006.38 (-0.32%)
PPCB : 0.5400 (-6.90%)
HOTH : 0.9900 (-1.00%)
^BTCUSD : 87,909.12 (-0.33%)

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

3rd Resistance Point 1.0500
2nd Resistance Point 1.0400
1st Resistance Point 1.0200
Last Price 0.9900
1st Support Level 0.9900
2nd Support Level 0.9800
3rd Support Level 0.9600

See More

52-Week High 3.8000
Fibonacci 61.8% 2.6005
Fibonacci 50% 2.2300
Fibonacci 38.2% 1.8595
Last Price 0.9900
52-Week Low 0.6600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar